KBP-336
KBP-336 is a dual amylin and calcitonin receptor agonist (DACRA). KBP-336 exhibits antidiabetic and insulin-sensitizing properties, improves glucose levels, spatial learning, and memory in diabetic rats, and reduces blood glucose. KBP-336 also alleviates pain-like symptoms in osteoarthritis rats. KBP-336 also promotes weight and fat reduction. KBP-336 is useful for research on diabetes, obesity, and arthritis.
For research use only. We do not sell to patients.
- Formula: C172H287N43O56S2
- Molecular Weight:3917.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vivo
KBP-336 (0.5-4.5 nmol/kg; subcutaneous injection; every 72 hours; 6-8 weeks) alleviates pain-like symptoms and reduces body weight and adipose tissue in rats with high-fat diet-induced obesity combined with medial meniscectomy[2].
KBP-336 (4.5 nmol/kg; subcutaneous injection; once every 3 days; 8 weeks) exhibits anti-obesity activity in high-fat diet-induced obese rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Zucker Diabetic Fatty Rats (male, 6-7 weeks old, fed Purina Laboratory Diet #5008, left untreated for 3 weeks to develop diabetes)[1]
-
Dosage:4.5 nmol/kg
-
Administration:s.c.; every 3 days; 127 days
-
Result:Significantly improved spatial learning.
Improved fasting blood glucose levels, reduced tAUC of fasting blood glucose and improved HbA1c levels.
Improved glucose tolerance, preserved plasma insulin levels and prevented eye cataract development.
-
Animal Model:Sprague Dawley rats (high-fat diet-fed with medial meniscectomy)[2]
-
Dosage:0.5 nmol/kg; 1.5 nmol/kg; 4.5 nmol/kg
-
Administration:s.c.; every 72 hours; 6 and 8 weeks
-
Result:Significantly increased the 50% paw withdrawal threshold (PWT), indicating relieved pain-like symptoms.
Induced significant weight loss and reduced inguinal and perirenal adipose tissue masses at doses of 1.5 and 4.5 nmol/kg.
Did not affect body weight or fat depots, still effectively alleviated pain at 0.5 nmol/kg dose.
-
Animal Model:Sprague-Dawley rats (male, 5-6 weeks, high-fat diet)[3]
-
Dosage:4.5 nmol/kg
-
Administration:s.c.; every 3 days; 8 weeks
-
Result:Significantly reduced body weight and adiposity, improved glucose homeostasis, delayed gastric emptying.
Increased oligomycininduced leak respiration and the activity of citrate synthase and β-hydroxyacetyl-CoA-dehydrogenase.
Chemical Information
-
Molecular Weight 3917.50
-
Formula C172H287N43O56S2
-
Sequence
Ac-Cys-Ala-Ser-Leu-Ser-Thr-Cys-{Aib}-Leu-Gly-Arg-Leu-Ser-Ala-Glu-Leu-His-Lys(AEEA-AEEA-γGlu-C18 diacid)-Ala-Thr-Tyr-Pro-Lys-Thr-Asp-Val-Gly-Ala-Asn-Ala-Pro-NH2
-
Sequence Shortening
Ac-CASLSTC-{Aib}-LGRLSAELH-Lys(AEEA-AEEA-γGlu-C18 diacid)-ATYPKTDVGANAP-NH2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Protocol for Water Maze
The Morris Water Maze is a rodent spatial learning and memory assay in which a mouse or rat swims in opaque water to find an escape platform; in the hidden-platform version, the animal cannot see the platform and must use distal extra-maze cues to learn its fixed spatial location. The assay primarily measures hippocampus-dependent spatial learning during acquisition trials and spatial reference memory during probe trials after platform removal; readouts include escape latency, swim path length, swim speed, quadrant occupancy, platform-site crossings, and proximity to the former platform location.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
[1]. Petersen EA, et al. DACRA induces profound weight loss, satiety control, and increased mitochondrial respiratory capacity in adipose tissue. Int J Obes (Lond). 2024 Oct;48(10):1421-1429. [Content Brief]
[2]. Larsen AT, et al. The Insulin Sensitizer KBP-336 Prevents Diabetes-Induced Cognitive decline in ZDF Rats. J Prev Alzheimers Dis. 2024;11(4):1122-1131. [Content Brief]
[3]. Mohamed KE, et al. The dual amylin and calcitonin receptor agonist KBP-336 elicits a unique combination of weight loss, antinociception and bone protection - a novel disease-modifying osteoarthritis drug. Arthritis Res Ther. 2024;26(1):129. Published 2024 Jul 12. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)